Header Logo

Connection

ANN LEEN to T-Lymphocytes

Back to Details
This is a "connection" page, showing publications ANN LEEN has written about T-Lymphocytes.
ANN LEEN
Connection Strength
4.824
T-Lymphocytes
  1. Secreted Fas Decoys Enhance the Antitumor Activity of Engineered and Bystander T Cells in Fas Ligand-Expressing Solid Tumors. Cancer Immunol Res. 2022 11 02; 10(11):1370-1385.
    View in: PubMed
    Score: 0.440
  2. Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant. Blood. 2021 05 13; 137(19):2585-2597.
    View in: PubMed
    Score: 0.398
  3. Dynamics of virus-specific T cell immunity in pediatric liver transplant recipients. Am J Transplant. 2018 09; 18(9):2238-2249.
    View in: PubMed
    Score: 0.327
  4. Characterizing the Cellular Immune Response to Parainfluenza Virus 3. J Infect Dis. 2017 07 15; 216(2):153-161.
    View in: PubMed
    Score: 0.305
  5. Preventing stem cell transplantation-associated viral infections using T-cell therapy. Immunotherapy. 2015; 7(7):793-810.
    View in: PubMed
    Score: 0.267
  6. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014 Jun 25; 6(242):242ra83.
    View in: PubMed
    Score: 0.247
  7. Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol Ther. 2014 Jun; 22(6):1211-1220.
    View in: PubMed
    Score: 0.242
  8. Antiviral T-cell therapy. Immunol Rev. 2014 Mar; 258(1):12-29.
    View in: PubMed
    Score: 0.241
  9. T-cell therapy: the next generation. Expert Rev Hematol. 2010 Apr; 3(2):123-5.
    View in: PubMed
    Score: 0.184
  10. Improving T cell therapy for cancer. Annu Rev Immunol. 2007; 25:243-65.
    View in: PubMed
    Score: 0.147
  11. Contact-activated monocytes: efficient antigen presenting cells for the stimulation of antigen-specific T cells. J Immunother. 2007 Jan; 30(1):96-107.
    View in: PubMed
    Score: 0.147
  12. Adenoviral infections in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006 Mar; 12(3):243-51.
    View in: PubMed
    Score: 0.139
  13. T-cell immunotherapy for adenoviral infections of stem-cell transplant recipients. Ann N Y Acad Sci. 2005 Dec; 1062:104-15.
    View in: PubMed
    Score: 0.136
  14. T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects. J Clin Oncol. 2021 05 01; 39(13):1415-1425.
    View in: PubMed
    Score: 0.097
  15. Identification of protective T-cell antigens for smallpox vaccines. Cytotherapy. 2020 11; 22(11):642-652.
    View in: PubMed
    Score: 0.093
  16. Evaluation of cyclin A1-specific T cells as a potential treatment for acute myeloid leukemia. Blood Adv. 2020 Jan 28; 4(2):387-397.
    View in: PubMed
    Score: 0.091
  17. Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity. J Immunother Cancer. 2019 11 28; 7(1):330.
    View in: PubMed
    Score: 0.090
  18. Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment. Cancer Discov. 2018 08; 8(8):972-987.
    View in: PubMed
    Score: 0.081
  19. Asian Elephant T Cell Responses to Elephant Endotheliotropic Herpesvirus. J Virol. 2018 03 15; 92(6).
    View in: PubMed
    Score: 0.080
  20. Immunologic Profiling of Human Metapneumovirus for the Development of Targeted Immunotherapy. J Infect Dis. 2017 09 15; 216(6):678-687.
    View in: PubMed
    Score: 0.077
  21. Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2017 Nov 01; 35(31):3547-3557.
    View in: PubMed
    Score: 0.077
  22. Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes. J Allergy Clin Immunol. 2016 05; 137(5):1498-1505.e1.
    View in: PubMed
    Score: 0.069
  23. Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood. 2014 Jun 19; 123(25):3895-905.
    View in: PubMed
    Score: 0.061
  24. Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol Ther. 2014 Mar; 22(3):623-633.
    View in: PubMed
    Score: 0.059
  25. Engineered T cells for cancer treatment. Cytotherapy. 2014 Jun; 16(6):713-33.
    View in: PubMed
    Score: 0.059
  26. Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer. Prostate Cancer Prostatic Dis. 2013 Jun; 16(2):123-31, S1.
    View in: PubMed
    Score: 0.056
  27. Enhancing immune reconstitution: from bench to bedside. Biol Blood Marrow Transplant. 2013 Jan; 19(1 Suppl):S79-83.
    View in: PubMed
    Score: 0.055
  28. T-cell therapy: a powerful tool for the management of viral infections and relapse post hematopoietic stem cell transplantation. Expert Rev Hematol. 2012 Oct; 5(5):471-3.
    View in: PubMed
    Score: 0.055
  29. Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma. J Immunother. 2012 Feb-Mar; 35(2):159-68.
    View in: PubMed
    Score: 0.052
  30. Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4. Clin Cancer Res. 2011 Nov 15; 17(22):7058-66.
    View in: PubMed
    Score: 0.051
  31. Engineered T cells for pancreatic cancer treatment. HPB (Oxford). 2011 Sep; 13(9):643-50.
    View in: PubMed
    Score: 0.050
  32. Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience. Cytotherapy. 2010 Oct; 12(6):743-9.
    View in: PubMed
    Score: 0.048
  33. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood. 2009 Aug 27; 114(9):1958-67.
    View in: PubMed
    Score: 0.043
  34. Autologous designer antigen-presenting cells by gene modification of T lymphocyte blasts with IL-7 and IL-12. J Immunother. 2007 Jul-Aug; 30(5):506-16.
    View in: PubMed
    Score: 0.038
  35. Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 Jun; 39(11):677-86.
    View in: PubMed
    Score: 0.037
  36. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006 Oct; 12(10):1160-6.
    View in: PubMed
    Score: 0.036
  37. Molecular dynamics at immune synapse lipid rafts influence the cytolytic behavior of CAR T cells. Sci Adv. 2025 Jan 10; 11(2):eadq8114.
    View in: PubMed
    Score: 0.032
  38. Phenotypic and functional characterization of posoleucel, a multivirus-specific T cell therapy for the treatment and prevention of viral infections in immunocompromised patients. Cytotherapy. 2024 Aug; 26(8):869-877.
    View in: PubMed
    Score: 0.030
  39. Therapy With Allogeneic Severe Acute Respiratory Syndrome Coronavirus-2-Specific T Cells for Persistent Coronavirus Disease 2019 in Immunocompromised Patients. Clin Infect Dis. 2023 09 11; 77(5):696-702.
    View in: PubMed
    Score: 0.029
  40. T cell immune profiling of respiratory syncytial virus for the development of a targeted immunotherapy. Br J Haematol. 2023 08; 202(4):874-878.
    View in: PubMed
    Score: 0.029
  41. General and Virus-Specific Immune Cell Reconstitution after Double Cord Blood Transplantation. Biol Blood Marrow Transplant. 2015 Jul; 21(7):1284-90.
    View in: PubMed
    Score: 0.016
  42. Absence of systemic immune response to adenovectors after intraocular administration to children with retinoblastoma. Mol Ther. 2010 Oct; 18(10):1885-90.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.